content_image/202962.jpg
## PART II 

## ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 

## Price Range of Common Shares 

Our common shares trade on the New York Stock Exchange (“NYSE”) and the NYSE Euronext Amsterdam Stock Exchange (“NYSE Euronext Amsterdam”) under the symbol “CLB”. The range of high and low sales prices per share of the common shares as reported by the NYSE and NYSE Euronext Amsterdam are set in the following table for the periods indicated: 

<img src='content_image/202962.jpg'>

(1)  Our common shares were admitted for trading on the NYSE Euronext Amsterdam on May 16, 2012. 

On February 12, 2014, the closing price, as quoted by the NYSE, was $182.30 per share and there were 44,855,765 common shares issued and outstanding held by approximately 186 record holders and approximately 66,557 beneficial holders. These amounts exclude shares held by us as treasury shares. 

See Part III, “Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” for discussion of equity compensation plans. 

## Dividend Policy 

In July 2008, Core Laboratories announced the initiation of a cash dividend program. Cash dividends of $0.32 and $0.28 per share were paid each quarter of 2013 and 2012, respectively. The declaration and payment of future dividends will be at the discretion of the Supervisory Board of Directors and will depend upon, among other things, future earnings, general financial condition, liquidity, capital requirements, and general business conditions. On January 13, 2014, the Company declared a cash dividend of $0.50 per share to be paid on February 21, 2014. 

Because we are a holding company that conducts substantially all of our operations through subsidiaries, our ability to pay cash dividends on the common shares is also dependent upon the ability of our subsidiaries to pay cash dividends or otherwise distribute or advance funds to us and on the terms and conditions of our existing and future credit arrangements. See “Liquidity and Capital Resources” included in “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.” 

